|
|
|
17.12.25 - 00:30
|
China′s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms? (SCMP)
|
|
|
Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable.
Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural......
|
|
|
|
|
|
|
|
|
|
|
16.12.25 - 08:01
|
Enhertu approved in US for 1L HER2+ metastatic BC (Cision)
|
|
|
16 December 2025
Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo's Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of more than three years
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the...
|
|
|
|
|
11.12.25 - 18:42
|
Kyowa Kirin meldet geplante Ernennung von Abdul Mullick zum President und Chief Executive Officer – bisheriger CEO Masashi Miyamoto bleibt Chairman (Business Wire)
|
|
|
Wechsel in der Unternehmensführung werden nach Abschluss der Hauptversammlung im März 2026 wirksam
Bekanntgabe folgt auf ein Jahr mit dualem CEO-/COO-Modell und bedeutet Rückkehr zur Führungsstruktur mit Einzelspitze
TOKIO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), ein weltweit tätiges Spezialpharmaunternehmen mit Sitz in Japan, gab heute die Entscheidung des Board of Directors bekannt, Dr. Abdul Mullick, derzeit President und Chief Operating Officer (COO), zum President und Chief Executive Officer (CEO) zu ernennen. Die Ernennung wird im März 2026 nach Abschluss der Aktionärshauptversammlung wirksam. Während Herr Mullick die Position des President und CEO von Kyowa Kirin übernimmt, behält der derzeitige CEO, Dr. Masashi Miyamoto, seine Position als Chairman.
Im März 2025 stimmten die Aktionäre einem dualen CEO-/COO-Modell zu. Mullick wurde in die neu geschaffene Position des Chief Operating Officer berufen, um gemeinsam mit Miyamoto das globale Unternehmen zu leiten. D...
|
|
|
11.12.25 - 13:12
|
Silent Dissenters as Fed Cuts, US Seizes Sanctioned Oil Tanker off Venezuela | The Pulse 12/11/2025 (Bloomberg)
|
|
|
The US Federal Reserve cut rates by a quarter percentage point for the third consecutive time. The vote was split 9-3 and details from the meeting show growing division among policymakers. The Fed maintained its outlook for just one cut in 2026, but the wording of its statement was subtly altered to suggest greater uncertainty around the timing.
The US military seized an oil tanker off the coast of Venezuela, in a serious escalation of tensions. The tanker was sanctioned by the US in 2022, for supporting Iranian oil exports. Venezuela's leaders described it as "blatant theft" and an "act of piracy."
Today's guests: Derek Halpenny, MUFG, Global Markets Head of Research; Noubar Afeyan, Flagship Pioneering Founder & CEO and Moderna Co-Founder; Jimmy Wales, Wikipedia Co-Founder; Jim O'Neill, UK House of Lords Members and former Goldman Sachs Asset Management Chairman (Source: Bloomberg)...
|
|
|
|
|
11.12.25 - 08:33
|
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman (Business Wire)
|
|
|
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026
Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader Structure
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman.
In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mu...
|
|
|
|
|
|
|
|
|
|
|
09.12.25 - 00:33
|
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer′s Disease Included in China′s Commercial Insurance Innovative Drug List (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
